<DOC>
	<DOCNO>NCT02447640</DOCNO>
	<brief_summary>This open label study , non-randomized , positron emission tomography ( PET ) study investigate mGlu5 receptor occupancy single two oral dose ADX48621 healthy subject use [ 18F ] -FPEB radiotracer .</brief_summary>
	<brief_title>PET Imaging Study Evaluate mGlu5r Occupancy Following ADX48621 ( Dipraglurant ) Administration</brief_title>
	<detailed_description>This open label study , non-randomized , positron emission tomography ( PET ) study investigate mGlu5 receptor occupancy single two oral dose ADX48621 healthy subject use [ 18F ] -FPEB . The study consist 2 part . Part 1 : A receptor occupancy dose curve obtain use adaptive design . Subjects undergo two [ 18F ] -FPEB PET image session : baseline plus scan treatment one dose ADX48621 . The second scan take Tmax ADX48621 ( 1 hour post dose ) . 100 mg initial dose proven efficacious P2A study Parkinson 's patient . This open label study , non-randomized , positron emission tomography ( PET ) study investigate mGlu5 receptor occupancy single two oral dose ADX48621 healthy subject use [ 18F ] -FPEB radiotracer.The maximum dose give 200 mg. Part 2 : The time course receptor occupancy study dose give 70 % receptor occupancy determine Part 1 . Two subject receive 2 dos ADX48621 2 separate day undergo three [ 18F ] -FPEB PET image session : baseline scan , post dose scan 1 post dose scan 2 . Subjects give ADX48621 one hour prior post dose scan 1 . The 2nd dose give morning approximately 4-6 hour prior post dose scan 2 . The post dose scan 2 performed afternoon . The maximum dose give 400 mg .</detailed_description>
	<criteria>Healthy male female , 1860 year old BMI 1832 kg/m2 Female subject must meet one follow criterion : Surgically sterile ( e.g . hysterectomy , bilateral oophorectomy , tubal ligation ) least 6 month prior screen Postmenopausal ( menstrual bleeding least 1 year prior screen confirm plasma FSH level &gt; 40 IU/L ) Nonpregnant , non lactate woman childbearing potential practicing contraception ( e.g . hormonal birth control , intra uterine device , condom spermicide ) Able comprehend willing sign Informed Consent Form ( ICF ) . Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator ) . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator . History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( except appendectomy hernia repair allow ) . Use tobaccocontaining nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior consent . Poor peripheral venous access . Participation clinical drug study within 30 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Volunteers</keyword>
</DOC>